{"page":{"totalFilteredElements":75},"studies":[{"active":true,"description":"Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma","eudractNumber":"2022-501810-77","id":8724,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06006117","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-17T09:09:16+02:00","shortTitle":"MARSUN","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)</div>","eudractNumber":"2019-002264-27","id":8440,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"}],"nctNumber":"NCT04111978","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-03-06T13:49:03+01:00","shortTitle":"MATAO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator&#8217;s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma","eudractNumber":"2023-510322-32","id":9816,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-02T09:52:31+02:00","shortTitle":"MERUS MCLA-158-CL02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma","eudractNumber":"2023-510323-30-00","id":9815,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06525220","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-10T14:21:22+02:00","shortTitle":"MERUS MCLA-158-CL03","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC<div><br /></div><div>AIO-PAK-0219<br /></div>","eudractNumber":"2023-503558-10-00","id":9825,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-26T14:03:02+02:00","shortTitle":"METAPANC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Klinische Pr&#252;fung der Phase III von CPX-351 zur Behandlung von Kindern mit Myeloischer Leuk&#228;mie mit Down-Syndrom 2018","eudractNumber":"2018-002988-25","id":8960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-02-22T12:45:46+01:00","shortTitle":"ML-DS 2018","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT)","eudractNumber":"2021-002864-36","id":10399,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT05429632","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-25T08:46:36+02:00","shortTitle":"MOTRANS - PKRPC001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","eudractNumber":"2021-002531-27","id":10386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05243797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-08-29T14:00:40+02:00","shortTitle":"MajesTEC-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC \nand Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and \nLenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in \nParticipants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended \nfor Autologous Stem Cell Transplant as Initial Therapy&#160;","eudractNumber":"2022-000909-28","id":9487,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05552222","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T14:01:36+02:00","shortTitle":"MajesTEC-7, 64007957MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma","eudractNumber":"2023-505436-35-00","id":11544,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-12-01T10:14:00+01:00","shortTitle":"MorningLyte","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}